FINWIRES · TerminalLIVE
FINWIRES

HKG:3696

26 stories mentioning HKG:3696Updated just now

Every FINWIRES story that references HKG:3696, newest first.

What's the latest news on HKG:3696?

Asia

InSilico Bags Significant AI Lab Collaboration Contract; Shares Rise 4%

InSilico Medicine (HKG:3696) said Monday it will collaborate with an unnamed AI lab to develop frontier models to support biological research under a contract valued at up to tens of millions of U.S. dollars, according to a same-day filing with the bourse.The duo will leverage InSilico's MMAI Gym training framework and data from its previous scientific studies, and will share revenue under the terms of their agreement, which the company did not disclose.InSilico's shares were last up 4% on the HKEX.

HKG:3696
Asia

InSilico Medicine Chairman/CEO Boosts Shareholding

InSilico Medicine (HKG:3696) Chairman and CEO Aleksandrs Zavoronkovs has increased his stake in the company by purchasing an additional 113,500 shares, according to a Monday bourse filing.The biotech company said Zavoronkovs purchased the shares on the open market between Sept. 4 and Sept. 7 using personal funds.Following the purchase, Zavoronkovs now owns 46,757,000 shares, or about 8.02% of outstanding shares.

HKG:3696
Asia

InSilico Doses First Patient in Phase III Trial for Rentosertib

InSilico Medicine (HKG:3696) has dosed the first patient in China for a Phase III trial of its treatment for idiopathic pulmonary fibrosis, according to a Thursday bourse filing.The GENESIS-IPF-3 study will run for 52 weeks, during which researchers will observe data from 320 subjects receiving Rentosertib, the biotechnology company said.InSilico said the study will determine whether the company's treatment is effective in a larger group over a longer period than the Phase IIa trial.

HKG:3696
Asia

Hong Kong Stocks Rise on Easing Rate Fears; InSilico Medicine Gains 4%

Hong Kong stocks closed higher Friday after U.S. Federal Reserve Governor Christopher Waller's comments eased concerns over another U.S. rate hike, lifting sentiment ahead of U.S. jobs data.The Hang Seng Index gained 437.56 points, or 1.7%, to close at 25,650.87, while the Hang Seng China Enterprises Index rose 169.79 points, or 2%, to 8,555.03.Waller said he would favor keeping interest rates steady if inflation continues to cool, helping boost global markets. Investors also watched developments in China's artificial intelligence sector after Moonshot AI reportedly filed confidentially for a Hong Kong IPO seeking to raise about $3 billion.Baidu (HKG:9888) which completed conversion from a secondary listing to a dual primary listing on the Hong Kong Stock Exchange earlier this week rose nearly 5%.In corporate developments, KFM Kingdom (HKG:3816) said it was unaware of reasons for unusual share price and trading activity, while its major shareholder KIG Real Estate said it was exploring potential transactions involving the company. KFM Kingdom shares rose nearly 4%InSilico Medicine (HKG:3696) also rose nearly 4% after Chairman Aleksandrs Zavoronkovs said he plans to buy up to HK$16 million of the company's shares in the secondary market this month using his personal funds.

Hang SengHKG:3696HKG:3816HKG:9888
Asia

InSilico Medicine Chairman Earmarks HK$16 Million to Boost Shareholding

InSilico Medicine (HKG:3696) Chairman Aleksandrs Zavoronkovs plans to purchase additional shares of the company this month, allocating up to HK$16 million, according to a Friday bourse filing.Zavoronkovs will purchase the shares in the secondary market using his personal funds, the biotech firm said.

HKG:3696
Asia

InSilico Medicine Completes $305 Million Zero-Coupon Convertible Bond Issue

InSilico Medicine (HKG:3696) completed the issuance of $305 million zero-coupon convertible bonds due in 2027, with net proceeds of about $301.6 million, according to a Thursday Hong Kong bourse filing.The company plans to allocate 40% of net proceeds to clinical trials and drug R&D, and another 30% to expand its R&D team by more than 200 experts across four regions.The remaining proceeds will fund scientific foundation models, including for biological target discovery and longevity-related diseases, as well as working capital and other corporate purposes.The bonds were issued on Sept. 3.Trading on the Vienna MTF is expected to begin around Sept. 4, and the company has obtained approval to list shares issuable upon conversion on the Hong Kong Stock Exchange.

HKG:3696
Asia

Value Partners, Insilico Medicine Plan AI, Life Sciences CVC Fund

Value Partners Group (HKG:0806), Insilico Medicine (HKG:3696), Shanghai Pudong Development Group, and Pudong Construction plan to jointly establish a RMB-denominated corporate venture capital fund.The fund will focus on artificial intelligence and life sciences, according to a statement on Tuesday.Value Partners' onshore private fund manager will serve as the fund's general partner and manager.The parties plan to combine capital and industry resources to invest across the AI and life sciences ecosystem.

HKG:0806HKG:3696
Asia

Insilico Medicine Cayman TopCo to Establish New Investment Fund

Insilico Medicine Cayman TopCo (HKG:3696) plans to establish a new investment fund, worth 302.5 million yuan, via its wholly-owned subsidiary Insilico Medicine, according to a Tuesday filing with the Hong Kong bourse.The fund, focused on the biopharmaceutical sector and other related industries, will be possibly named Insilico Pudong Development Value Partners (Shanghai) Private Equity Investment Fund Partnership, or the Insilico Medicine Exponential Technology Fund.As part of the proposed structure, Insilico Medicine's wholly owned subsidiary plans to contribute 3 million yuan to establish a joint venture with Shanghai Pudong Construction and its controlling shareholder. The contribution would represent 60% of the joint venture's 5 million yuan registered capital, the filing said.Shares of Insilico Medicine Cayman TopCo fell nearly 8% at market close.

HKG:3696
Asia

InSilico Medicine to Join MSCI Global Small Cap Indexes

InSilico Medicine Cayman TopCo (HKG:3696) will be added to the MSCI Global Small Cap Indexes, effective after the market close on Aug. 31.The inclusion will increase the company's representation in international small-cap benchmarks and may broaden its institutional investor base, the company said in a Monday Hong Kong exchange filing.Shares of the company rose nearly 1% in recent trade.

HKG:3696
Asia

Insilico Medicine's Pleural Mesothelioma Drug Receives US FDA Fast Track Designation; Shares Down 4%

Insilico Medicine (HKG:3696) said ISM6331 received fast-track designation from the U.S. Food and Drug Administration for the treatment of adult patients with unresectable malignant pleural mesothelioma, according to a Wednesday filing with the Hong Kong Stock Exchange.The company said the designation covers adult patients with unresectable malignant pleural mesothelioma.Shares of the biopharmaceutical company were down 4% in recent trade.

HKG:3696
Asia

Hong Kong Stocks Extend Gains Despite China's GDP Miss; Insilico Medicine Climbs

Hong Kong stocks held their momentum Wednesday as stronger-than-expected Chinese industrial output and retail sales data offset concerns over the country's weakest quarterly economic growth in more than three years.The Hang Seng Index rose 1.4%, or 340.37 points, to close at 24,681.10, while the Hang Seng China Enterprises Index gained 1%, or 81.30 points, to finish at 8,184.38.China's economy expanded 4.3% year over year in the second quarter, slowing from 5% in the previous quarter and marking its weakest pace of growth since the fourth quarter of 2022.However, June industrial output rose 5.3% from a year earlier, and retail sales increased 1%, with both figures exceeding analysts' expectations, suggesting resilience in economic activity.In corporate news, Insilico Medicine (HKG:3696) advanced over 10% after entering a strategic alliance with Bora Pharmaceuticals (TPE:6472) to collaborate on AI-driven drug discovery and development.

Hang SengHKG:3696
Asia

Insilico Medicine, Bora Pharmaceuticals Form AI Drug Discovery Alliance

Insilico Medicine (HKG:3696) said it entered into a strategic alliance with Bora Pharmaceuticals (TPE:6472) to collaborate on AI-driven drug discovery and development under a framework that could be valued at over $2.5 billion if fully implemented.The proposed collaboration, subject to the execution of definitive agreements, will combine Insilico's Pharma.AI platform for target discovery, generative chemistry and molecule optimization with Bora's drug development, manufacturing, quality and commercialization capabilities.The alliance aims to integrate AI-enabled drug discovery with development and manufacturing to accelerate the delivery of medicines for patients with unmet medical needs, according to a Wednesday news release.

HKG:3696TPE:6472
Asia

InSilico Medicine, CMS Expand Drug Development Partnership

InSilico Medicine (HKG:3696) expanded its collaboration with China Medical System (HKG:0867, SGX:8A8) to jointly develop innovative drugs for central nervous system diseases, according to a Monday filing with the Hong Kong bourse.Under the agreement, InSilico will combine its artificial intelligence drug discovery platform with CMS' research and development capabilities and therapeutic expertise to advance the programs.InSilico said it is eligible to receive milestone payments of up to 1.20 billion yuan, plus royalties based on net sales under the collaboration.

HKG:0867HKG:3696SGX:8A8
Asia

Insilico Medicine Forecasts Swing to Profit in H1; Shares Up 7%

Insilico Medicine (HKG:3696) said it expects net profit of $33.5 million to $39.5 million for the first half of 2026, a turnaround from the $19.2 million net loss recorded a year earlier, according to a Hong Kong bourse filing on Thursday.The firm attributed the turnaround to an expected 273% to 287% rise in revenue, to $102.5 million to $106.5 million, up from $27.5 million in the prior-year period.Shares of the company were up nearly 7% in recent morning trade.

HKG:3696
Asia

Insilico Medicine Strikes Drug Discovery Deal With Japan's Takeda Pharmaceutical

Insilico Medicine (HKG:3696) struck a drug discovery deal with Japan's Takeda Pharmaceutical (TYO:4502) that could net the company up to $600 million.In a Hong Kong bourse filing Thursday, Insilico Medicine said it will use its artificial intelligence-powered Pharma.AI platform to advance drug candidates across multiple therapeutic areas for Takeda.Insilico said the deal is valued at $600 million after accounting for the $60 million project initiation fee plus milestone payments. The company will also receive royalties on sales of commercialized drugs.

HKG:3696TYO:4502
Asia

Hong Kong Stocks Decline on Renewed U.S.-China Friction; Shenzhen HQVT Technology Shines on Debut

Hong Kong stocks fell on Monday as investors reacted to unchanged Chinese lending rates and renewed U.S.-China tensions after Beijing imposed export controls on several American entities.The Hang Seng Index fell 0.7%, or 156.29 points, to close at 23,768.52, while the Hang Seng China Enterprises Index dropped 0.8%, or 61.30 points, to finish at 7,914.74.The People's Bank of China kept the one-year loan prime rate, the benchmark for most corporate and household loans, at 3.00%, while the five-year rate, a reference for mortgage lending, remained at 3.50%.Meanwhile, China's Commerce Ministry added 10 U.S. entities to its export control list, immediately banning exports of dual-use items to those companies. The ministry said the measures were taken to safeguard national security and interests, describing them as a response to what it called the U.S. government's "malicious practices."The move followed Washington's recent decision to add several Chinese companies to a military-related entity list.In corporate news, Shenzhen HQVT Technology (HKG:1392) made its Hong Kong debut, closing nearly 271% higher at HK$26.70, compared with its offer price of HK$7.20.Insilico Medicine (HKG:3696) closed over 4% higher after entering a neuroimmune drug discovery collaboration with SK Biopharmaceuticals (KRX:326030), with the deal carrying a potential value of more than $2.5 billion.

Hang SengHKG:1392HKG:3696
Asia

Insilico Medicine, SK Biopharmaceuticals Strike $2.5 Billion AI Drug Discovery Pact

Insilico Medicine (HKG:3696) and SK Biopharmaceuticals (KRX:326030) have signed a drug discovery collaboration deal focused on neuroimmune disorders of the central nervous system, with a total potential value exceeding $2.5 billion, according to a Monday Hong Kong bourse filing.Under the agreement, Insilico will use its artificial intelligence-powered Pharma.AI platform and drug discovery capabilities to identify and optimize drug candidates. Whereas, SK Biopharmaceuticals will lead late-stage development and commercialization, the filing said.Insilico is eligible to receive up to $18 million in upfront and near-term milestone payments. The total potential value of the deal exceeds $2.5 billion, including development, regulatory, and commercial milestones, as well as single-digit royalties on future product sales.The collaboration focuses on neuroimmune diseases and expands Insilico's use of AI-driven drug discovery technologies in central nervous system disorders.

HKG:3696KRX:326030
Asia

InSilico Medicine Completes First Human Dosing of Parkinson's Disease Drug in Phase 1 Trial

InSilico Medicine Cayman (HKG:3696) completed first-in-human dosing in a phase 1 clinical trial of ISM8969, according to a Wednesday Hong Kong bourse filing.The oral NLRP3 inhibitor is being developed to treat chronic neuroinflammation and central nervous system disorders, including Parkinson's disease.The milestone marks the first clinical achievement under the company's co-development collaboration with Hygtia Therapeutics.

HKG:3696
Asia

Insilico Medicine to Join FTSE Global Equity Index Series

Insilico Medicine (HKG:3696) will be added to the FTSE Global Equity Index Series following FTSE Russell's quarterly review, according to a Monday Hong Kong bourse filing.The artificial intelligence drug discovery company will join the FTSE Global Small Cap Index, FTSE Global All Cap Index, and FTSE Global Total Cap Index, with the changes taking effect on June 22.

HKG:3696
Asia

InSilico Medicine Says No Decision Made on Abu Dhabi Secondary Listing

InSilico Medicine (HKG:3696) said it has not made any concrete decision on a secondary listing at this stage and will make further announcements if there are any material developments, according to a Wednesday Hong Kong bourse filing.Bloomberg reported earlier, citing people familiar with the matter, that the AI-driven drug discovery company was considering a secondary listing in Abu Dhabi, potentially becoming the first company from outside the Gulf to list shares on a regional exchange.The report said InSilico Medicine had held preliminary discussions about a listing on the Abu Dhabi Securities Exchange as early as this year.

HKG:3696

Showing 1-20 of 26

Track with the FINWIRES app suite